ADHD Remote Treatment

Remote ADHD treatment has been one of the most consequential, and most chaotic, parts of telehealth. Demand is high. Diagnosis is complicated. Stimulants are tightly controlled. The rules around remote prescribing have been changing year to year. This page lays out the territory: how diagnosis should work, what the prescribing rules require, and what to look for in a service that intends to be around in a year.

The short version

ADHD diagnosis should involve a structured history, validated rating scales, ruling out other conditions, and (for adults) functional impairment in multiple settings.
Stimulants are Schedule II controlled substances. Remote prescribing of Schedule II drugs has been governed by the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, with COVID-era flexibilities that have been repeatedly extended.
The DEA has proposed permanent rules; the final state of those rules is still in flux. Verify the current rule directly with the DEA.
Some services that prescribed stimulants on a "diagnosis-by-questionnaire" model have exited the space or been reorganized.
Finding a stable prescriber for ongoing stimulant care can take months. Continuity matters more in this space than almost any other.
Non-stimulant ADHD medications exist and may be remotely prescribed without the same Schedule II constraints.

What an evaluation should include

An ADHD evaluation should not be a five-minute checklist. It should include developmental history (symptoms in childhood are part of the diagnostic criteria for adult ADHD), a current symptom inventory, validated rating scales (the ASRS for adults; teacher and parent rating scales for children), and a deliberate effort to rule out other conditions that mimic or coexist with ADHD: anxiety, depression, sleep disorders, thyroid disease, substance use, and learning disabilities. Functional impairment in multiple settings — work, home, relationships — is part of the diagnostic threshold.

Done well, an initial evaluation is at least an hour and may be split across visits. Done poorly, it is an online questionnaire and a quick prescription. The latter has been the basis of regulatory and journalistic scrutiny of several high-volume services. A reasonable evaluation does not have to happen in person, but it does have to do the work.

The prescribing landscape

The Ryan Haight Act

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires an in-person medical evaluation before a controlled substance can be prescribed via the internet, with limited exceptions. The Act was a response to online prescribing of opioids, predating modern telehealth. It applies to all schedules, but the consequences are most visible for Schedule II drugs (stimulants used for ADHD, certain pain medications).

COVID-era flexibilities

Beginning in 2020, the DEA and HHS used emergency authority to waive the in-person evaluation requirement, allowing controlled substances to be prescribed via telehealth without a prior in-person visit. This made remote ADHD treatment broadly available for the first time. The flexibilities were initially tied to the public health emergency.

The proposed permanent rule

Since the public health emergency ended, the DEA has issued proposed rules and a series of extensions of the flexibilities while it works toward a permanent framework. Drafts have included options to allow some controlled substance telehealth prescribing without an in-person visit, subject to limits, and options for "telemedicine special registrations" for specific clinicians. As of this writing the rules continue to evolve. Anyone making a clinical or business decision based on the current state of the rule should verify directly with the DEA's published guidance — see controlled substances and remote prescribing for more.

State medical boards

State boards may impose additional requirements on telehealth controlled substance prescribing, sometimes stricter than federal floor. The Federation of State Medical Boards (FSMB) provides resources, but each state's rules apply where the patient is physically located. See cross-state licensing.

Why some platforms exited the space

A wave of telehealth ADHD platforms launched during the pandemic on a model that combined questionnaire-based intake, brief video visits, and recurring stimulant refills. Several attracted regulatory scrutiny — from the DEA, the Department of Justice, and state medical boards — and some have been the subject of investigations, restructurings, or operational changes. Pharmacies have at times refused to fill prescriptions written by certain platforms. The practical effect for patients has been disruption: prescribers leaving, prescriptions not filling, services pivoting to non-controlled medications or therapy-only models.

None of this means remote ADHD care is intrinsically problematic. It means the model that scaled fastest — minimal evaluation, maximum prescription volume — was the model that broke. Services that took diagnosis seriously have generally fared better.

Continuity is the central problem

Stimulants for ADHD typically require regular follow-up: monthly prescriptions, periodic in-person evaluation depending on the regulatory framework, and ongoing assessment of effect and side effects. The single biggest predictor of useful long-term ADHD treatment is whether you can see the same prescriber over time. Services with high prescriber turnover create gaps in care, repeated re-evaluations, and the constant friction of transferring records.

Before signing up, ask: how long have prescribers been with this practice? Will I see the same person at every visit, or whoever is available? What happens if my prescriber leaves? How are records transferred to a new clinician?

Non-stimulant options

Non-stimulant ADHD medications include atomoxetine (a norepinephrine reuptake inhibitor) and certain alpha-2 agonists (guanfacine, clonidine), as well as several other agents used clinically. Bupropion is sometimes used off-label. None of these are Schedule II controlled substances, which simplifies remote prescribing under federal rules. They are not equivalent to stimulants for everyone — efficacy and side-effect profiles differ — but they are reasonable options to discuss, especially when stimulant access is unstable. A prescriber who refuses to discuss non-stimulant options, or who prescribes only one specific brand, is a flag.

What an ethical service looks like

Initial evaluation that takes an hour or more, often across multiple visits.
Validated rating scales as inputs to (not substitutes for) clinical judgment.
Active ruling out of other conditions: sleep, mood, anxiety, substance use, thyroid.
Discussion of non-medication treatments — behavioral interventions, coaching, accommodations, therapy.
Discussion of stimulant and non-stimulant options including risks and side effects.
A named prescriber you can see again, not a roster of strangers.
Adherence to current DEA and state rules, including any in-person visit requirement.
Clear policy on what happens if you travel out of state — see cross-state licensing.
Coordination with your primary care or therapist, when relevant.
Transparent pricing, including the cost of refills and any membership.

Adolescents and children

For minors, ADHD evaluation typically involves rating scales completed by parents and teachers, a developmental history, and consideration of comorbidities (learning disabilities, anxiety). Pediatric prescribing of stimulants is common but is generally embedded in an ongoing pediatric or child-and-adolescent psychiatry relationship rather than a stand-alone telehealth service. See telehealth for children.

Side effects and what to monitor

Stimulant medications have well-known side effects: appetite suppression, sleep disruption, blood pressure and heart rate elevation, mood changes, and rarer effects. Routine monitoring includes blood pressure, weight, and questions about sleep, mood, and any cardiovascular symptoms. A prescriber who never asks about these, or who never measures vital signs, is providing inadequate care. Home BP monitoring may be useful — see measuring your own vitals at home.

Red flags in remote ADHD services

Diagnosis from a 10-minute call or a questionnaire alone.
No effort to rule out other conditions.
One condition, one drug, no follow-up other than refills.
Frequent prescriber turnover or no clinician name visible.
Refusal to share notes or records.
Aggressive marketing, especially on social media targeting "self-diagnosis."
Vague or shifting answers about DEA compliance.
Pressure to switch from a non-stimulant to a stimulant before non-medication options are considered.

For more on patterns to avoid, see red flags in any remote care service.

What to ask before starting

What does the initial evaluation include, and how long does it take?
Does this service comply with current DEA telehealth rules for Schedule II prescribing? Is an in-person visit required at any point?
Will I see the same prescriber every time?
What happens if I travel out of state for work or school?
What are my options if a stimulant does not work or is not available?
Will you communicate with my primary care provider or therapist?
What does this cost, including refills and any monthly fee?

When this is not enough

Some patients are better served in person, especially those with significant comorbid conditions, complex psychiatric histories, or substance use considerations. ADHD coexists with anxiety, depression, sleep disorders, and substance use at high rates; an integrated team — primary care, psychiatry, therapy — is often better than a single-condition platform. See mental health telehealth and choosing a mental health platform. Acute crisis is 988 (US Suicide and Crisis Lifeline) or 911.